<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03336645</url>
  </required_header>
  <id_info>
    <org_study_id>SHP615-301</org_study_id>
    <nct_id>NCT03336645</nct_id>
  </id_info>
  <brief_title>Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan</brief_title>
  <official_title>A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy, safety and pharmacokinetics of
      MHOS/SHP615 administered buccally in children with status epilepticus (convulsive) in a
      healthcare setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Anticipated">November 27, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 27, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Therapeutic Success</measure>
    <time_frame>From start of study drug administration up to 30 minutes (mins) postdose</time_frame>
    <description>Therapeutic success will be defined as the cessation of visible seizure activity within 10 minutes (mins) with a sustained absence of visible seizure activity for 30 minutes following a single dose of SHP615.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Whose Seizure Event Stopped Within 10 Minutes of Single Dose of SHP615 and who Have Sustained Absence of Seizure Activity for at least 1 Hour</measure>
    <time_frame>From start of study drug administration up to 1 h postdose</time_frame>
    <description>Percentage of participants whose seizure event stopped within 10 mins of single dose administration of SHP615 and who have sustained absence of seizure activity for at least 1 h will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Whose Seizure Event Stopped Within 10 Minutes of Single Dose of SHP615 and who Have Sustained Absence of Seizure Activity for at least 4 Hours</measure>
    <time_frame>From start of study drug administration up to 4 h postdose</time_frame>
    <description>Percentage of participants whose seizure event stopped within 10 mins of single dose administration of SHP615 and who have sustained absence of seizure activity for at least 4 h will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Whose Seizure Event Stopped Within 10 Minutes of Single Dose of SHP615 and who Have Sustained Absence of Seizure Activity for at least 6 Hours</measure>
    <time_frame>From start of study drug administration up to 6 h postdose</time_frame>
    <description>Percentage of participants whose seizure event stopped within 10 mins of single dose administration of SHP615 and who have sustained absence of seizure activity for at least 6 h will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of seizures (Convulsions)</measure>
    <time_frame>From start of study drug administration until resolution of seizure</time_frame>
    <description>Time to resolution of seizures (convulsions) from the administration of SHP615.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recovery of Consciousness</measure>
    <time_frame>From start of study drug administration until recovery of consciousness</time_frame>
    <description>Time to recovery of consciousness from the administration of SHP615.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Require Additional Anticonvulsant Medication for Ongoing status epilepticus (SE) 10 Minutes After Single Dose Administration of SHP615</measure>
    <time_frame>10 mins postdose</time_frame>
    <description>Percentage of participants who require additional anticonvulsant medication for ongoing SE according to the participating healthcare setting protocol or guideline, 10 mins after a single dose of SHP615.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Fail to Respond to Treatment</measure>
    <time_frame>10 mins postdose</time_frame>
    <description>Treatment failure or nonresponder is defined as continuing seizure activity and/or the need for any additional rescue medication according to the participating healthcare setting protocol or guideline, 10 mins after a single dose of SHP615.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Depression</measure>
    <time_frame>Baseline up to 4 h postdose</time_frame>
    <description>Persistent decrease in oxygen saturation to &lt;92% measured at 10 minutes, 30 minutes, and 4, 6, and 24 hours postdose (ie, &lt;92% on room air for 2 minutes or more after dosing while monitoring [per healthcare setting protocol and/or the clinical judgment of the physician]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspiration Pneumonia</measure>
    <time_frame>Baseline up to 24 h postdose</time_frame>
    <description>Diagnosis of aspiration pneumonia after single dose administration of SHP615.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation or Agitation as Measured by Riker Sedation-Agitation Scale</measure>
    <time_frame>Baseline, 0, 10 and 30 mins, 1, 4, 6 and 24 h postdose</time_frame>
    <description>Riker Sedation-Agitation Scale is a arousal/sedation tool ranging from 1 (unarousable condition) to 7 (Dangerous agitation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline up to 24 h postdose</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs are defined as AEs that start or deteriorate on or after the date of the first dose of investigational product and no later than 3 days following the last dose of investigational product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Vital Signs Reported as an Adverse Event</measure>
    <time_frame>Baseline up to 24 h postdose</time_frame>
    <description>Vital signs include blood pressure, pulse rate, respiratory rate and body temperature. A change in the value of vital sign assessment can represent an AE if the change is clinically relevant or if, during treatment with the investigational product, a shift of a parameter is observed from a normal value to an abnormal value, or a further worsening of an already abnormal value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Clinical Laboratory Results Reported as an Adverse Event (AE)</measure>
    <time_frame>Baseline up to Week 1</time_frame>
    <description>Clinical laboratory (serum biochemistry and urinalysis) results out-of-range will be assessed and if they are clinically significant will be reported as AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Oxygen Saturation</measure>
    <time_frame>Baseline, 10 and 30 mins, 4, 6 and 24 h postdose</time_frame>
    <description>Oxygen saturation at baseline will be measured and recorded on room air. The investigator will record the oxygen saturation as well as the oxygen delivery system and amount of oxygen administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Reported as an Adverse Event (AE)</measure>
    <time_frame>Baseline up to 24 h postdose</time_frame>
    <description>12-lead ECG will be performed. Any clinically significant change in ECG assessment will be reported as AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Buccal Irritation</measure>
    <time_frame>1, 4 and 6 h postdose</time_frame>
    <description>Buccal cavity will be examined for redness, inflammation, and ulceration.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>SHP615</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram [mg/kg] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHP615</intervention_name>
    <description>SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).</description>
    <arm_group_label>SHP615</arm_group_label>
    <other_name>Midazolam hydrochloride oromucosal solution</other_name>
    <other_name>MHOS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female participants whose corrected gestational age is greater than or equal
             to (&gt;=) 52 weeks (gestational weeks plus the number of weeks after birth) and less
             than (&lt;) 18 years (and weight greater than [&gt;] 5 kilogram [kg]), at the time of
             investigational product administration. If the participant's exact age is not known,
             the participant should be excluded.

          -  Parent, guardian, or legally authorized representative (LAR) of the child provides
             informed consent (and assent, when applicable per Shire policy and country
             regulations) to participate in the study prior to participation in any protocol
             specific procedures. The participant may be prescreened by the investigator in their
             clinical practice and the parent, guardian, or LAR may sign informed consent before
             the participant presents to the healthcare setting for treatment of the seizure.

          -  Participant with generalized tonic-clonic SE with seizures accompanied by loss of
             consciousness with any of the following characteristics persistent at the time of
             study drug administration:

               1. Currently presenting with seizure (convulsive) activity and 3 or more convulsions
                  within the preceding hour

               2. Currently presenting with seizure (convulsive) and 2 or more convulsions in
                  succession without recovery of consciousness

               3. Currently presenting with a single seizure (convulsive) lasting &gt;=5 mins

        Exclusion Criteria:

          -  Female participants who are pregnant, suspected to be pregnant, or nursing.

          -  Subjects with major trauma, not necessarily restricted to the head, as the cause of
             the seizure.

          -  Subjects with seizures due to illegal drug or acute alcoholic intoxication.

          -  Subjects with known or suspected recurrent seizures due to illegal drug or alcohol
             withdrawal.

          -  Subjects with history of seizures of psychogenic origin.

          -  Subjects with seizures due to severe encephalitis or meningitis, as determined by the
             PI

          -  Subjects with known history of hypersensitivities, non-responsiveness or
             contraindications to benzodiazepines (ie, clinically significant respiratory
             depression, severe acute hepatic failure, myasthenia gravis, syndrome of sleep apnea,
             glaucoma with closed angle, use of concomitant drugs determined by the investigator to
             have a contraindication to the use of benzodiazepines.)

          -  Subjects with a known history of benzodiazepine abuse.

          -  Subjects who, in the judgment of the healthcare provider, have not responded to
             previous administrations of midazolam systemic therapies, including Midafresa and/or
             Dormicum.

          -  Subjects who need emergent surgical intervention and general anesthesia/intubation.

          -  Subjects with significant hypotension and cardiac dysrhythmia (example [eg],
             atrioventricular [AV] block of second or third degree, VT [ventricular tachycardia]).

          -  Subjects who have been receiving human immunodeficiency virus (HIV) protease
             inhibitors or HIV reverse transcriptase inhibitors.

          -  Subjects with current hypoglycemia (glucose &lt;60 milligram per deciliter [mg/dL]) upon
             presentation at the hospital or healthcare setting.

          -  Subjects with severe cerebral anoxia (except cerebral palsy), in the judgment of the
             healthcare provider.

          -  Subjects have used an investigational product or been enrolled in a clinical study
             (including vaccine studies) that, in the investigator's opinion, may impact this
             Shire-sponsored study.

          -  Subjects has received antiseizure medication prior to arrival in the healthcare
             setting.

          -  Subjects has prior placement of a vagus nerve stimulator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>216 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Study Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yamanashi Prefectural Central Hospital</name>
      <address>
        <city>Kofu</city>
        <state>Fujimi</state>
        <zip>400-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takuaki Oba</last_name>
      <email>t-oba@epsogo.co.jp</email>
    </contact>
    <investigator>
      <last_name>Yusuke Goto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gifu Prefectural General Medical Center</name>
      <address>
        <city>Gifu</city>
        <state>Gifu Prefecture</state>
        <zip>500-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayumi Sasada</last_name>
      <email>sasada.mayumi@neues.co.jp</email>
    </contact>
    <investigator>
      <last_name>Atsushi Imamura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chika Holloway</last_name>
      <email>holloway@huhp.hokudai.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Hideaki Shiraishi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital</name>
      <address>
        <city>Tokyo</city>
        <state>Kawadacho</state>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Keiko Sato</last_name>
      <email>keiko.yagi@miraca.com</email>
    </contact>
    <investigator>
      <last_name>Hirokazu Oguni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHO Minami-Okayama Medical Center</name>
      <address>
        <city>Okayama</city>
        <state>Okayama Prefecture</state>
        <zip>701-0304</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miyuzu Taniguchi</last_name>
      <email>taniguchi.miyuzu@nagasaki-mc.com</email>
    </contact>
    <investigator>
      <last_name>Harumi Yoshinaga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Yachiyo Medical Center</name>
      <address>
        <city>Yachiyo</city>
        <state>Owada Shinden</state>
        <zip>276-8524</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juri Obata</last_name>
      <email>juri-obata@irom.co.jp</email>
    </contact>
    <investigator>
      <last_name>Junichi Takanashi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jichi Children's Medical Center Tochigi</name>
      <address>
        <city>Saitama-shi</city>
        <state>Saitama-ken</state>
        <zip>330-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kuniko Suzuki</last_name>
      <email>ksuzuki@jichi.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Hitoshi Osaka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shizuoka Institute of Epilepsy and Neurological Disorders</name>
      <address>
        <city>Shizuoka</city>
        <state>Shizuoka Prefecture</state>
        <zip>420-8688</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshiaki Yamamoto</last_name>
      <email>yamamoty@shizuokamind.org</email>
    </contact>
    <investigator>
      <last_name>Asako Horino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fukuoka Children's Hospital(NW)</name>
      <address>
        <city>Fukuoka</city>
        <zip>813-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shino Ohmura</last_name>
      <email>s-ohmura@epsogo.co.jp</email>
    </contact>
    <investigator>
      <last_name>Ryutaro Kira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHO Hokkaido Medical Center</name>
      <address>
        <city>Hokkaidō</city>
        <zip>063-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshiyuki Hori</last_name>
      <email>horiyel@hok-mc.hosp.go.jp</email>
    </contact>
    <investigator>
      <last_name>Masayoshi Nagao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kumamoto Saishunso National Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-1196</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akiko Nishioka</last_name>
      <email>anishioka@saisyunsou1.hosp.go.jp</email>
    </contact>
    <investigator>
      <last_name>Chizuru Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHO Nagasaki Medical Center</name>
      <address>
        <city>Nagasaki</city>
        <zip>856-8562</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miyuzu Taniguchi</last_name>
      <email>taniguchi.miyuzu@nagasaki-mc.com</email>
    </contact>
    <investigator>
      <last_name>Shigeki Tanaka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHO Nishi Niigata Chuo National Hospital</name>
      <address>
        <city>Niigata</city>
        <zip>950-2085</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emi Takahashi</last_name>
      <email>chiken-kango01@masa.go.jp</email>
    </contact>
    <investigator>
      <last_name>Jun Tohyama</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aichi Children's Health and Medical Center(NW)</name>
      <address>
        <city>Obu</city>
        <zip>474-8710</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yukiko Sone</last_name>
      <email>sone.yukiko@e-smo.co.jp</email>
    </contact>
    <investigator>
      <last_name>Kazuya Itomi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-0914</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hiroto Okuda</last_name>
      <email>okuda-h@cc.okayama-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Katsuhiro Kobayashi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nakano Children's Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>535-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Atsuko Nakata</last_name>
      <email>at-nakata@epsogo.co.jp</email>
    </contact>
    <investigator>
      <last_name>Kiyotaka Murakami</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka Women's and Children's Hospital(NW)</name>
      <address>
        <city>Osaka</city>
        <zip>594-1101</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michiko Yamazaki</last_name>
      <email>michiko@mch.pref.osaka.jp</email>
    </contact>
    <investigator>
      <last_name>Yasuhiro Suzuki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saitama Children's Medical Center(NW)</name>
      <address>
        <city>Saitama</city>
        <zip>330-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mika Arai</last_name>
      <email>mk-arai@epsogo.co.jp</email>
    </contact>
    <investigator>
      <last_name>Shinichiro Hamano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nozomi Okuda</last_name>
      <email>okuda.nozomi@neues.co.jp</email>
    </contact>
    <investigator>
      <last_name>Haruo Shintaku</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Center Hospital, NCNP</name>
      <address>
        <city>Tokyo</city>
        <zip>187-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hiroko Harada</last_name>
      <email>chiken27@ncnp.go.jp</email>
    </contact>
    <investigator>
      <last_name>Eiji Nakagawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tottori University Hospital</name>
      <address>
        <city>Tottori</city>
        <zip>683-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yoshihiro Maegaki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Yamadaoka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miyuki Takamura</last_name>
      <email>miyuki-takamura@ocrcn.or.jp</email>
    </contact>
    <investigator>
      <last_name>Kuriko Shimono</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kanagawa Children's Medical Center(NW)</name>
      <address>
        <city>Yokohama</city>
        <zip>232-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emiko Miura</last_name>
      <email>emiura@kcmc.jp</email>
    </contact>
    <investigator>
      <last_name>Tomohide Goto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Seizure</keyword>
  <keyword>Midazolam hydrochloride</keyword>
  <keyword>Convulsive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Status Epilepticus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

